Vical Incorporated (NASDAQ:VICL) traded up 13.1% during mid-day trading on Thursday following insider buying activity. The company traded as high as $1.21 and last traded at $1.21. 764,127 shares traded hands during mid-day trading, an increase of 251% from the average session volume of 217,698 shares. The stock had previously closed at $1.07.
Specifically, major shareholder Armistice Capital, Llc bought 145,297 shares of the firm’s stock in a transaction on Wednesday, June 13th. The stock was acquired at an average cost of $1.07 per share, with a total value of $155,467.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.58% of the stock is currently owned by insiders.
A number of brokerages have recently commented on VICL. Zacks Investment Research lowered shares of Vical from a “hold” rating to a “sell” rating in a research note on Thursday, May 10th. HC Wainwright set a $5.00 price target on shares of Vical and gave the stock a “buy” rating in a research note on Monday, May 7th. Finally, ValuEngine upgraded shares of Vical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
Vical (NASDAQ:VICL) last announced its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.12). Vical had a negative return on equity of 32.93% and a negative net margin of 144.80%. The company had revenue of $0.72 million during the quarter, compared to the consensus estimate of $2.10 million. research analysts anticipate that Vical Incorporated will post -1.08 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in VICL. Geode Capital Management LLC grew its position in Vical by 195.0% during the fourth quarter. Geode Capital Management LLC now owns 111,688 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 73,822 shares during the period. Millennium Management LLC bought a new stake in Vical during the fourth quarter valued at approximately $256,000. Sabby Management LLC bought a new stake in Vical during the fourth quarter valued at approximately $503,000. Ariel Investments LLC grew its position in Vical by 9.6% during the fourth quarter. Ariel Investments LLC now owns 637,913 shares of the biotechnology company’s stock valued at $1,167,000 after buying an additional 55,669 shares during the period. Finally, Stonepine Capital Management LLC bought a new stake in Vical during the fourth quarter valued at approximately $1,238,000. Institutional investors own 44.44% of the company’s stock.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.